Disclosure of Conflicts of Interest
The authors declare no competing
financial interests.
Reference
[1] Young NS. Aplastic anemia. N Engl J Med.
2018;379(17):1643–1656.
[2] Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic
anemia: a prospective multicenter study. Haematologica.
2008;93(4):518–523.
[3] Helge D Hartung, Timothy S Olson, Monica Bessler. Acquired
aplastic anemia in children. Pediatric clinics of North America 2013
Dec;60(6):1311-36.
[4] Scott A Peslak, Timothy Olson, Daria V Babushok. Diagnosis and
Treatment of Aplastic Anemia[J]. Current Treatment Options in
Oncology, 2017, 18(12):70.
[5] Scheinberg P, Wu C O, Nunez O, et al. Long-term outcome of
pediatric patients with severe aplastic anemia treated with
antithymocyte globulin and cyclosporine. [J]. Journal of Pediatrics,
2008, 153(6):814-819.e1.
[6] Rogers Z R, Nakano T A, Olson T S, et al. Immunosuppressive
therapy for pediatric aplastic anemia: a North American Pediatric
Aplastic Anemia Consortium study[J]. Haematologica, 2019.
[7] Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for
severe aplastic anemia in children: bone marrow transplantation from a
matched family donor versus immunosuppressive therapy. [J].
Haematologica, 2014, 99(12):1784-91.
[8] Carlo, Dufour, Marta, et al. Outcome of aplastic anemia in
adolescence: a survey of the Severe Aplastic Anemia Working Party of the
European Group for Blood and Marrow Transplantation. [J].
Haematologica, 2014, 99(10):1574-81.
[9] Garanito M P, Carneiro J D A, Filho V O, et al. Outcome of
children with severe acquired aplastic anemia treated with rabbit
antithymocyte globulin and cyclosporine A, [J]. Jornal de Pediatria,
2014.
[10] Dufour C, Pillon M, G Sociè, et al. Outcome of aplastic anaemia
in children. A study by the severe aplastic anaemia and paediatric
disease working parties of the European group blood and bone marrow
transplant. [J]. British Journal of Haematology, 2015, 169.
[11] Townsley D M, Scheinberg P, Winkler T, et al. Eltrombopag Added
to Standard Immunosuppression for Aplastic Anemia[J]. New England
Journal of Medicine, 2017, 376(16):1540-1550.
[12] Matthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
The New England journal of medicine 2012 Jul 05;367(1):11-9.
[13] Régis Peffault de Latour, Austin Kulasekararaj, Simona
Iacobelli, et al. Eltrombopag Added to Immunosuppression in Severe
Aplastic Anemia. The New England journal of medicine 2022 01
06;386(1):11-23
[14] Emma M. Groarke, Bhavisha A. Patel, Fernanda
Gutierrez-Rodrigues, et al. Eltrombopag added to immunosuppression for
children with treatment naive severe aplastic anaemia[J]. British
Journal of Haematology, 2021, 192, 605–614.
[15] Harry Lesmana, Timothy Jacobs, Michelle Boals, et al.
Eltrombopag in children with severe aplastic anemia. Pediatric blood &
cancer 2021 08;68(8): e29066.
[16] Olga Goronkova, Galina Novichkova, Tatiana Salimova, et al.
Efficacy of combined immunosuppression with or without eltrombopag in
children with newly diagnosed aplastic anemia. Blood advances 2022 Apr
21.
[17] Subspecialty Group of Hematology, Society of Pediatrics,
Chinese Medical Association The
Editorial Board, Chinese Journal of Pediatrics. Recommendations for
diagnosis and treatment of acquired aplastic anemia in children.
Zhonghua Er Ke Za Zhi. 2014;52(2):103–106.
[18] Erickson-Miller C. Preclinical activity of eltrombopag
(SB-497115), an oral, nonpeptide thrombopoietin receptor agonist[J].
Stem Cells, 2009, 27.
[19] Filippidou M, Avgerinou G, Tsipou H, et al. Longitudinal
evaluation of eltrombopag in paediatric acquired severe aplastic
anaemia. Br J Haematol. 2020;190(3): e157–e173. doi:10.
1111/bjh.16766.
[20] Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in
children with immunethrombocytopenia. Blood Adv. 2018;2(4):454–461.
doi:10.1182/bloodadvances.2017010660.
Table 1: Characteristics of the patients at baseline